Pharma BD Deal Intelligence
Sanofi acquired Translate Bio for $3.2 billion in all-cash ($38.00/share; announced Aug 4, 2021, closed Sep 14, 2021), buying out its mRNA partner to take full ownership of an mRNA vaccine and therapeutics platform and anchor Sanofi's new mRNA Center of Excellence (Cambridge, MA and Lyon, France). The lead rationale was next-generation mRNA vaccines, with seasonal influenza and COVID-19 as the priority applications and cystic fibrosis (inhaled MRT5005) among the earlier therapeutic programs. Post-close, the platform underdelivered against its original thesis: the MRT5005 CF program showed no lung-function benefit and was dropped, and at its Q4/full-year 2025 results (Jan 29, 2026) Sanofi confirmed it had deprioritized/discontinued its mRNA-based seasonal flu vaccine program (SP0237, a hexavalent mRNA candidate in Phase 1/2 that protected against influenza A but struggled against B strains), stating it does not anticipate launching an mRNA seasonal flu product in the near term. Sanofi says it remains committed to mRNA and is advancing a Phase 1/2 mRNA pandemic H5 avian-flu vaccine with encouraging early data, while leaning on its established Fluzone High-Dose and Flublok franchises for seasonal flu.